Monopar TherapeuticsMNPR
MNPR
About: Monopar Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients. The company's pipeline consists of Validive for the prevention of chemoradiotherapy-induced severe oral mucositis in oropharyngeal cancer patients, camsirubicinfor the treatmentof soft tissue sarcoma, a late-stage preclinical antibody, MNPR-101, for cancers and severe COVID-19 and an early-stage camsirubicin analog, MNPR-202, for various cancers.
Employees: 16
0
Funds holding %
of 7,425 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory disclosures by fund managers ($100M+ AUM)
53,861% more capital invested
Capital invested by funds: $106K [Q3] → $57.1M (+$57M) [Q4]
200% more funds holding
Funds holding: 6 [Q3] → 18 (+12) [Q4]
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
41.96% more ownership
Funds ownership: 0.45% [Q3] → 42.41% (+41.96%) [Q4]
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
Low target
$40
4%
downside
Avg. target
$58
39%
upside
High target
$76
82%
upside
2 analyst ratings
2 positive
100%
0 neutral
0%
0 negative
0%
HC Wainwright & Co. Sean Lee 57% 1-year accuracy 17 / 30 met price target | 4%downside $40 | Buy Reiterated | 1 Apr 2025 |
Piper Sandler Biren Amin 22% 1-year accuracy 6 / 27 met price target | 82%upside $76 | Overweight Assumed | 19 Mar 2025 |
Financial journalist opinion
Neutral
GlobeNewsWire
1 day ago
Monopar Announces ALXN1840 Data Selected for Late-Breaker Presentation at EASL Congress 2025
WILMETTE, Ill., April 29, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced that data on the long term efficacy and safety of its ALXN1840 (tiomolybdate choline) drug candidate for Wilson disease has been accepted for a late-breaker poster presentation at the European Association for the Study of the Liver (“EASL”) International Liver Congress 2025. EASL is recognized as one of the premier events in the hepatology space and will be held in Amsterdam, Netherlands from May 7 – 10, 2025.
Neutral
GlobeNewsWire
1 month ago
Monopar Reports Fourth Quarter and Full-Year 2024 Financial Results and Recent Developments
WILMETTE, Ill., March 31, 2025 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biopharmaceutical company focused on developing innovative treatments for patients with unmet medical needs, today announced fourth quarter and full-year 2024 financial results and summarized recent developments.
Positive
Zacks Investment Research
1 month ago
Here's Why Momentum in Monopar Therapeutics (MNPR) Should Keep going
Monopar Therapeutics (MNPR) made it through our "Recent Price Strength" screen and could be a great choice for investors looking to make a profit from stocks that are currently on the move.
Neutral
PRNewsWire
3 months ago
Rosalind Franklin University's Helix 51 Incubator Welcomes Monopar Therapeutics
Monopar's pipeline includes clinical-stage radiopharmaceuticals targeting advanced solid tumors and late-stage ALXN1840, a treatment for Wilson Disease NORTH CHICAGO, Ill. , Jan. 23, 2025 /PRNewswire/ -- Rosalind Franklin University of Medicine and Science announced that Monopar Therapeutics is the latest biotech company to join the Helix 51 biomedical incubator community.
Positive
Zacks Investment Research
3 months ago
MNPR Stock Skyrockets 384% in 3 Months After Deal With AZN
Monopar stock skyrockets 384% in three months following a licensing deal with AstraZeneca for a late-stage Wilson Disease candidate.
Positive
Zacks Investment Research
4 months ago
What Awaits These 4 Biotech Stocks That More Than Doubled in 2024
Here are four drug and biotech stocks, ARQT, MESO, MNPR and KOD, which have more than doubled in 2024 with room for further growth in 2025.
Positive
Seeking Alpha
4 months ago
Monopar: Radiopharmaceutical Company With 2 Radioisotope Development Pathways
MNPR-101-Lu is being developed in a phase 1 study to target advanced solid tumor patients with uPAR expression. MNPR-101-Zr is being used as an imaging agent to determine which advanced solid tumor patients is likely to respond to MNPR-101-Lu in a phase 1 study. The global solid tumor cancer treatment market size is projected to hit around $532.42 billion by 2032; uPAR expression is high in a variety of types of solid tumors.
Neutral
GlobeNewsWire
4 months ago
Monopar Therapeutics Inc. Announces Pricing of $40 Million Public Offering of Common Stock and Concurrent Private Placement of Pre-Funded Warrants
WILMETTE, Ill., Dec. 20, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR) (“Monopar” or the “Company”), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the pricing of an underwritten registered offering of 798,655 shares of its common stock at an offering price of $23.79 per share. In addition to the shares sold in the registered offering, Monopar announced the concurrent pricing of a private placement of pre-funded warrants to purchase 882,761 shares of common stock at a purchase price of $23.789 per pre-funded warrant, which represents the per share offering price for the common stock less the $0.001 per share exercise price for each pre-funded warrant. The gross proceeds to Monopar from the registered offering and private placement, before deducting the underwriting discounts and commissions and estimated offering expenses, are expected to be $40 million. The offering is expected to close on or about December 23, 2024, subject to customary closing conditions.
Neutral
GlobeNewsWire
4 months ago
Monopar Announces First Patient Dosed with its Novel Therapeutic Radiopharmaceutical MNPR-101-Lu
WILMETTE, Ill., Dec. 05, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced the first patient ever dosed with MNPR-101-Lu. This novel therapeutic radiopharmaceutical combines MNPR-101, Monopar's antibody that selectively targets the urokinase plasminogen activator receptor (uPAR), with the therapeutic radioisotope lutetium-177. uPAR is involved in tumor growth and metastasis, and is found in some of the most aggressive, deadly cancers, including pancreatic, ovarian, triple negative breast, and colorectal cancers.
Neutral
GlobeNewsWire
4 months ago
Monopar to Present at the 36th Annual Piper Sandler Healthcare Conference
WILMETTE, Ill., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (Nasdaq: MNPR), a clinical-stage biotechnology company focused on developing innovative treatments for patients with unmet medical needs, today announced that Chandler Robinson, MD, Monopar's Chief Executive Officer, will participate in a fireside chat along with one-on-one meetings at the 36th Annual Piper Sandler Healthcare Conference.
Charts implemented using Lightweight Charts™